Hcw Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
HCWB Nasdaq 8731 https://hcwbiologics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Hcw Biologics Inc

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights - Apr 1st, 2024 8:10 pm
Rebecca Byam Bought 122% More Shares In HCW Biologics - Feb 24th, 2024 12:44 pm
Several Insiders Invested In HCW Biologics Flagging Positive News - Jan 25th, 2024 10:41 am
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights - Nov 14th, 2023 12:00 pm
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting - Nov 8th, 2023 12:30 pm
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting - Nov 1st, 2023 11:30 am
Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics Inc - Sep 16th, 2023 3:00 pm
Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc - Sep 14th, 2023 5:27 pm
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023 - Sep 6th, 2023 11:30 am
Insider Stock Buying Reaches US$845k On HCW Biologics - Aug 18th, 2023 10:03 am
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights - Aug 11th, 2023 11:00 am
The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitable - Jul 7th, 2023 10:28 am
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders - Jun 14th, 2023 11:30 am
HCW Biologics First Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.057 loss in 1Q 2022) - May 10th, 2023 10:13 am
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights - May 9th, 2023 11:15 am
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan - Apr 27th, 2023 11:40 am